Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Dermatology and Therapy|December 10, 2025
Paving the Way to Healthcare Equity: A Comprehensive Review of Care Gaps and Emerging Initiatives in DermatologyAndrew Alexis, Raj Chovatiya, Susan Taylor, et al.
Advances in Therapy|December 3, 2025
Efficacy of Lebrikizumab on Pruritus: A Narrative ReviewGil Yosipovitch, Brian S Kim, Sonja Ständer, et al.
Kidney International Reports|September 19, 2022
Increased Rates of Supplement-Associated Oxalate Nephropathy During COVID-19 PandemicPeter Fong, Raghav Wusirika, Jose Rueda, et al.
Journal of Drugs in Dermatology : JDD|January 22, 2015
Optimizing the use of topical brimonidine in rosacea management: panel recommendationsEmil A Tanghetti, J Mark Jackson, Kevin Tate Belasco, et al.
Journal of Drugs in Dermatology : JDD|October 7, 2020
Impact of Atopic Dermatitis Lesion Location on Quality of Life in Adult Patients in a Real-world StudyPeter A Lio, Andreas Wollenberg, Jacob P Thyssen, et al.
American Journal of Clinical Dermatology|July 15, 2025
Efficacy and Safety of Lebrikizumab in Adult and Adolescent Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results from the Phase IIIb, Open-Label ADmirable StudyAndrew Alexis, Ali Moiin, Jill Waibel, et al.
Transplantation|March 9, 2002
Short course induction immunosuppression with thymoglobulin for renal transplant recipientsIrfan A Agha, Jose Rueda, Alejandro Alvarez, et al.
The Journal of Dermatological Treatment|March 12, 2026
Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitisJonathan I Silverberg, Thomas Bieber, Kilian Eyerich, et al.
Dermatology and Therapy|May 3, 2024
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic DermatitisEric L Simpson, Marjolein de Bruin-Weller, H Chih-Ho Hong, et al.
The Journal of Dermatological Treatment|July 25, 2025
Lebrikizumab improves head/neck/face dermatitis and erythema and does not increase treatment-emergent adverse events of head/neck/face erythema in patients with moderate-to-severe atopic dermatitisJenny E Murase, Kilian Eyerich, Raj Chovatiya, et al.
Pageof 4